Patents Represented by Attorney FibroGen, Inc.

Find this attorney in the Justia Lawyer Directory

  • HIF?prolyl hydroxylation assay
    Patent number: 7985563
    Abstract: The present invention provides methods of identifying compounds that decrease proline hydroxylation of the alpha subunit of hypoxia inducible factor (HIF?).
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: July 26, 2011
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: William G. Kaelin, Jr., Mircea Ivan
  • Recombinant gelatins
    Patent number: 6992172
    Abstract: The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: January 31, 2006
    Assignee: FibroGen, Inc.
    Inventors: Robert C. Chang, Kari I. Kivirikko, Thomas B. Neff, David R. Olsen, James W. Polarek
  • &agr;2-macroglobulin receptor as a receptor for CTGF
    Patent number: 6555322
    Abstract: The invention provides a connective tissue growth factor (CTGF) receptor and biochemical and/or biological equivalents, homologs, derivatives, subunits, fragments, and complexes thereof. The CTGF receptor is useful in the treatment and diagnosis of CTGF-associated disorders and in methods of screening for agents that effect CTGF receptor expression and activity. The invention further provides nucleic acid sequences encoding the CTGF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, antisense sequences and antibodies directed against CTGF receptor, and pharmaceutical compositions for use in treatment of CTGF-associated disorders.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: April 29, 2003
    Assignee: FibroGen, Inc.
    Inventors: Patricia R. Segarini, James E. Nesbitt, David F. Carmichael
  • N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
    Patent number: 6506936
    Abstract: The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: January 14, 2003
    Assignee: FibroGen, Inc.
    Inventor: Wen-Bin Ho
  • C-proteinase inhibitors
    Patent number: 6462063
    Abstract: The present invention relates to a novel class of N,N′-di substituted hydantoin hydroxamates capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: October 8, 2002
    Assignee: Fibrogen, Inc.
    Inventors: Wen-Bin Ho, Udo Bauer